Monday, December 16, 2019

Back Into Spark Therapeutics

Today, Roche (Ticker: RHHBY) received approval for its acquisition of Spark Therapeutics (Ticker: ONCE) from Britain’s Competition and Markets Authority (CMA). This was the catalysts I was looking for… I went back into Sparks today via common stock at an average price of $113.68 comprising of ~ 40% of my portfolio. I like the risk and reward at this point as the FTC was working close with Britain’s CMA during the review process. I’m modeling a year end close, which equates to a potential ~ 16% annualized rate of return. Not bad considering this is close to the finish line.


At December 18, 2019, Blogger DCFrancis said...

congrats on the move!

At December 18, 2019, Blogger Money Turtle said...

Thanks... It was a long wait.


Post a Comment

<< Home